1791 Alum Creek Drive
Columbus, OH
USA 43068
Email: gbrigham@maryhaven.com
Disclosure statement:
Qualified on the content I am responsible for because: The following publications relates directly to my presetnation in this session;
Brigham, G. S., Amass, L., Winhusen, T., Harrer, J. M., & Pelt, A. (2007). Using buprenorphine short-term taper to facilitate early treatment engagement. Journal of Substance Abuse Treatment, 32, 349-356.
Amass, L., Ling, W, Freese, TE, Reiber, C, Annon, JJ, Cohen, AJ, McCarty, D, Reid, MS, Brown, LS, Clark, C, Ziedonis, DM, Krejci, J, Stine, S, Winhusen, T, Brigham, G, Babcock, D, Muir, J, Buchan, B, Horton, T. (2004). Bringing Buprenorphine-Naloxone Detoxification to Community Treatment Providers: The NIDA Clinical Trials Network Field Experience. The American Journal on Addictions, 13: S42-S66.
Ling, W., Amass, L., Shoptaw, S., Annon, J., Hillhouse, M., Babcock, D., Brigham, G., Harrer, J., Reid, M., Muir, J., Buchan, B., Orr, D., Woody, G., Krejci, J., Ziedonis, D., and the Buprenorphine Study Protocol Group (2005). A multi center randomized trial of Buprenorphine-naloxone versus Clonidine for opioid detoxification: Findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction, 100, 1090-1000.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.